2017
DOI: 10.1590/0037-8682-0474-2016
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: This study indicates the need for pharmacotherapeutic monitoring in patients with Chagas because of the high number of therapeutic interventions, DRPs (approximately 3 DRPs/patient), BNZ adherence, and polypharmacy.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
6
0

Year Published

2017
2017
2023
2023

Publication Types

Select...
4

Relationship

1
3

Authors

Journals

citations
Cited by 4 publications
(6 citation statements)
references
References 19 publications
0
6
0
Order By: Relevance
“…2 Concentration in lM which reduced the proliferation of epimastigotes by 90%. 3 Concentration in cytotoxic lg ml À1 to 50% of RAW 267.4 cells. 4 IS 50 Selectivity index of 50% ¼ CC 50 /IC 50 .…”
Section: Anti-t Cruzi Activity In Vivomentioning
confidence: 99%
See 2 more Smart Citations
“…2 Concentration in lM which reduced the proliferation of epimastigotes by 90%. 3 Concentration in cytotoxic lg ml À1 to 50% of RAW 267.4 cells. 4 IS 50 Selectivity index of 50% ¼ CC 50 /IC 50 .…”
Section: Anti-t Cruzi Activity In Vivomentioning
confidence: 99%
“…In Latin America, five to eight million people are infected with this protozoan 1 . Infection starts by blood-sucking triatomine bugs, but others transmissions routes are possible, such as organ transplantation, congenital contamination, blood transfusion as well as contaminated foods and drinks 2,3 . Due to these modes of transmission the disease is spreading to nonendemic countries including Australia, Canada, Japan, Spain, and the USA 2,3 .…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…Then, in 2011, a pediatric dose of BNZ (12.5 mg) tablets began to be marketed, the result of an initiative by the Drugs for Neglected Diseases Initiative and Brazilian LAFEPE, the only producer of the drug. Nowadays, efforts are being made to develop more effective dosage forms, capable of increasing patient compliance and reduced toxic effects 4 6 .…”
Section: Introductionmentioning
confidence: 99%
“…Nevertheless, it is still used in the acute phase, with chances of cure, and in the chronic phase, preventing the disease progression. Therefore, as it is a worldwide public health problem, there is a certain urgency for the development of therapeutic alternatives 6 , 10 – 12 .…”
Section: Introductionmentioning
confidence: 99%